EUVIMEDEUVIMED entdecken
Leitlinie

Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults

Sangho Hyun iD, Chia-Hung Sze, Satyajeet Singh, Padideh Daneii iD, Jeffrey L Williams iD, Joel Fernandez iD

Journal of the American Heart Association · 12.11.2026

DOI: 10.1161/jaha.126.053443 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of the American Heart Association, online erschienen am 12.11.2026. Verfasst von Sangho Hyun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Lakeland Regional Health Medical Center Lakeland FL USA. Hauptthemen laut MEDLINE: Dyslipidemias, Hypolipidemic Agents, Practice Guidelines as Topic, Cardiology. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 2026 American College of Cardiology/American Heart Association dyslipidemia guideline replaces the pooled cohort equations with the atherosclerotic cardiovascular disease component of the Predicting Risk of Cardiovascular Disease Events equations for primary prevention risk estimation and modifies lipid‐lowering therapy (LLT) eligibility by lowering the risk‐based treatment threshold and expanding diabetes and chronic kidney disease criteria. The population‐level impact of this transition is uncertain.

Methods

We analyzed National Health and Nutrition Examination Survey 2021 to 2023 participants aged 40 to 75 years without self‐reported atherosclerotic cardiovascular disease and with available low‐density lipoprotein cholesterol. Survey weights were used to generate national estimates. Guideline‐supported LLT eligibility was assessed under the 2018 pooled cohort equations–based American College of Cardiology/American Heart Association cholesterol framework and the 2026 Predicting Risk of Cardiovascular Disease Events–based American College of Cardiology/American Heart Association dyslipidemia framework. Current LLT use was assessed among guideline‐supported adults.

Results

The analytic sample included 1662 participants, representing 115.05 million US adults. LLT was supported for 42.82 million adults under the 2018 framework and 42.17 million under the 2026 framework, a net decrease of 0.65 million. Reclassification was substantial: 37.42 million remained supported, 5.40 million lost support, 4.75 million newly gained support, and 67.48 million remained unsupported. Among supported adults, current LLT use was 39.4% under the 2018 framework and 40.5% under the 2026 framework.

Conclusions

Transition to the 2026 Predicting Risk of Cardiovascular Disease Events–based framework produced little net change in LLT eligibility but meaningfully changed who was supported for therapy. Persistent undertreatment remains a major implementation gap.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasHypolipidemic AgentsPractice Guidelines as TopicCardiologyCardiovascular DiseasesHumansMiddle AgedUnited StatesFemaleMaleAdultAmerican Heart AssociationAgedRisk AssessmentNutrition SurveysPrimary PreventionEligibility DeterminationRisk Factors

Stichwörter der Autor:innen

PREVENTdyslipidemialipid‐lowering therapypooled cohort equationsprimary prevention

Substanzen

Hypolipidemic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine Lakeland Regional Health Medical Center Lakeland FL USA.
  • Department of Cardiology Lakeland Regional Health Medical Center Lakeland FL USA.

ORCID-Profile: Sangho Hyun, Padideh Daneii, Jeffrey L Williams, Joel Fernandez

Zitieren

APA

Hyun, S., Sze, C. H., Singh, S., Daneii, P., Williams, J. L., & Fernandez, J. (2026). Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.053443

Vancouver

Hyun S, Sze CH, Singh S, Daneii P, Williams JL, Fernandez J. Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.053443

BibTeX
@article{Hyun2026,
  author = {Hyun, Sangho and Sze, Chia-Hung and Singh, Satyajeet and Daneii, Padideh and Williams, Jeffrey L and Fernandez, Joel},
  title = {Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.126.053443}
}
Kostenlos starten →